Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087760710> ?p ?o ?g. }
- W3087760710 endingPage "448" @default.
- W3087760710 startingPage "441" @default.
- W3087760710 abstract "Purpose To perform a planned interim analysis of acute (within 12 months) and late (after 12 months) toxicities and cosmetic outcomes after proton accelerated partial breast irradiation (APBI). Methods and Materials A total of 100 patients with pTis or pT1-2 N0 (≤3cm) breast cancer status after segmental mastectomy were enrolled in a single-arm phase 2 study from 2010 to 2019. The clinically determined postlumpectomy target volume, including tumor bed surgical clips and operative-cavity soft-tissue changes seen on imaging plus a radial clinical expansion, was irradiated with passively scattered proton APBI (34 Gy in 10 fractions delivered twice daily with a minimum 6-hour interfraction interval). Patients were evaluated at protocol-specific time intervals for recurrence, physician reports of cosmetic outcomes and toxicities, and patient reports of cosmetic outcomes and satisfaction with the treatment or experience. Results Median follow-up was 24 months (interquartile range [IQR], 12-43 months). Local control and overall survival were 100% at 12 and 24 months. There were no acute or late toxicities of grade 3 or higher; no patients experienced fat necrosis, fibrosis, infection, or breast shrinkage. Excellent or good cosmesis at 12 months was reported by 91% of patients and 94% of physicians; at the most recent follow-up, these were 94% and 87%, respectively. The most commonly reported late cosmetic effect was telangiectasis (17%). The total patient satisfaction rate for treatment and results at 12 and 24 months was 96% and 100%, respectively. Patients’ mean time away from work was 5 days (IQR, 2-5 days), and the median out-of-pocket cost was $700 (IQR, $100-$1600). The mean left-sided heart dose was 2 cGy (range, 0.2-75 cGy), and the mean ipsilateral lung dose was 19 cGy (range, 0.2-164 cGy). Conclusions Proton APBI is a maturing treatment option with high local control, favorable intermediate-term cosmesis, high treatment satisfaction, low treatment burden, and exceptional heart and lung sparing. To perform a planned interim analysis of acute (within 12 months) and late (after 12 months) toxicities and cosmetic outcomes after proton accelerated partial breast irradiation (APBI). A total of 100 patients with pTis or pT1-2 N0 (≤3cm) breast cancer status after segmental mastectomy were enrolled in a single-arm phase 2 study from 2010 to 2019. The clinically determined postlumpectomy target volume, including tumor bed surgical clips and operative-cavity soft-tissue changes seen on imaging plus a radial clinical expansion, was irradiated with passively scattered proton APBI (34 Gy in 10 fractions delivered twice daily with a minimum 6-hour interfraction interval). Patients were evaluated at protocol-specific time intervals for recurrence, physician reports of cosmetic outcomes and toxicities, and patient reports of cosmetic outcomes and satisfaction with the treatment or experience. Median follow-up was 24 months (interquartile range [IQR], 12-43 months). Local control and overall survival were 100% at 12 and 24 months. There were no acute or late toxicities of grade 3 or higher; no patients experienced fat necrosis, fibrosis, infection, or breast shrinkage. Excellent or good cosmesis at 12 months was reported by 91% of patients and 94% of physicians; at the most recent follow-up, these were 94% and 87%, respectively. The most commonly reported late cosmetic effect was telangiectasis (17%). The total patient satisfaction rate for treatment and results at 12 and 24 months was 96% and 100%, respectively. Patients’ mean time away from work was 5 days (IQR, 2-5 days), and the median out-of-pocket cost was $700 (IQR, $100-$1600). The mean left-sided heart dose was 2 cGy (range, 0.2-75 cGy), and the mean ipsilateral lung dose was 19 cGy (range, 0.2-164 cGy). Proton APBI is a maturing treatment option with high local control, favorable intermediate-term cosmesis, high treatment satisfaction, low treatment burden, and exceptional heart and lung sparing." @default.
- W3087760710 created "2020-09-25" @default.
- W3087760710 creator A5009965176 @default.
- W3087760710 creator A5016731809 @default.
- W3087760710 creator A5024466689 @default.
- W3087760710 creator A5040555528 @default.
- W3087760710 creator A5041542657 @default.
- W3087760710 creator A5041793550 @default.
- W3087760710 creator A5042331166 @default.
- W3087760710 creator A5044442638 @default.
- W3087760710 creator A5047507534 @default.
- W3087760710 creator A5071173748 @default.
- W3087760710 creator A5078458765 @default.
- W3087760710 creator A5088149497 @default.
- W3087760710 creator A5089277393 @default.
- W3087760710 date "2021-02-01" @default.
- W3087760710 modified "2023-10-13" @default.
- W3087760710 title "Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial" @default.
- W3087760710 cites W1964115081 @default.
- W3087760710 cites W1965029673 @default.
- W3087760710 cites W1967804683 @default.
- W3087760710 cites W1976367403 @default.
- W3087760710 cites W1978537515 @default.
- W3087760710 cites W1990637325 @default.
- W3087760710 cites W1990963883 @default.
- W3087760710 cites W1991383089 @default.
- W3087760710 cites W2001093915 @default.
- W3087760710 cites W2001231930 @default.
- W3087760710 cites W2002698038 @default.
- W3087760710 cites W2025968998 @default.
- W3087760710 cites W2029657612 @default.
- W3087760710 cites W2032535658 @default.
- W3087760710 cites W2044449451 @default.
- W3087760710 cites W2053230656 @default.
- W3087760710 cites W2067420088 @default.
- W3087760710 cites W2067450972 @default.
- W3087760710 cites W2078159140 @default.
- W3087760710 cites W2130746306 @default.
- W3087760710 cites W2141150135 @default.
- W3087760710 cites W2143280576 @default.
- W3087760710 cites W2146227526 @default.
- W3087760710 cites W2154375587 @default.
- W3087760710 cites W2171089302 @default.
- W3087760710 cites W2336914831 @default.
- W3087760710 cites W2519353639 @default.
- W3087760710 cites W2528451133 @default.
- W3087760710 cites W2810326358 @default.
- W3087760710 cites W2972581225 @default.
- W3087760710 cites W2992619229 @default.
- W3087760710 cites W2993667428 @default.
- W3087760710 doi "https://doi.org/10.1016/j.ijrobp.2020.09.009" @default.
- W3087760710 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32946965" @default.
- W3087760710 hasPublicationYear "2021" @default.
- W3087760710 type Work @default.
- W3087760710 sameAs 3087760710 @default.
- W3087760710 citedByCount "16" @default.
- W3087760710 countsByYear W30877607102021 @default.
- W3087760710 countsByYear W30877607102022 @default.
- W3087760710 countsByYear W30877607102023 @default.
- W3087760710 crossrefType "journal-article" @default.
- W3087760710 hasAuthorship W3087760710A5009965176 @default.
- W3087760710 hasAuthorship W3087760710A5016731809 @default.
- W3087760710 hasAuthorship W3087760710A5024466689 @default.
- W3087760710 hasAuthorship W3087760710A5040555528 @default.
- W3087760710 hasAuthorship W3087760710A5041542657 @default.
- W3087760710 hasAuthorship W3087760710A5041793550 @default.
- W3087760710 hasAuthorship W3087760710A5042331166 @default.
- W3087760710 hasAuthorship W3087760710A5044442638 @default.
- W3087760710 hasAuthorship W3087760710A5047507534 @default.
- W3087760710 hasAuthorship W3087760710A5071173748 @default.
- W3087760710 hasAuthorship W3087760710A5078458765 @default.
- W3087760710 hasAuthorship W3087760710A5088149497 @default.
- W3087760710 hasAuthorship W3087760710A5089277393 @default.
- W3087760710 hasConcept C119060515 @default.
- W3087760710 hasConcept C121608353 @default.
- W3087760710 hasConcept C126322002 @default.
- W3087760710 hasConcept C141071460 @default.
- W3087760710 hasConcept C168563851 @default.
- W3087760710 hasConcept C188816634 @default.
- W3087760710 hasConcept C2775944032 @default.
- W3087760710 hasConcept C2777757722 @default.
- W3087760710 hasConcept C2780943399 @default.
- W3087760710 hasConcept C2781467025 @default.
- W3087760710 hasConcept C530470458 @default.
- W3087760710 hasConcept C61943457 @default.
- W3087760710 hasConcept C71924100 @default.
- W3087760710 hasConceptScore W3087760710C119060515 @default.
- W3087760710 hasConceptScore W3087760710C121608353 @default.
- W3087760710 hasConceptScore W3087760710C126322002 @default.
- W3087760710 hasConceptScore W3087760710C141071460 @default.
- W3087760710 hasConceptScore W3087760710C168563851 @default.
- W3087760710 hasConceptScore W3087760710C188816634 @default.
- W3087760710 hasConceptScore W3087760710C2775944032 @default.
- W3087760710 hasConceptScore W3087760710C2777757722 @default.
- W3087760710 hasConceptScore W3087760710C2780943399 @default.
- W3087760710 hasConceptScore W3087760710C2781467025 @default.
- W3087760710 hasConceptScore W3087760710C530470458 @default.
- W3087760710 hasConceptScore W3087760710C61943457 @default.